Rockefeller Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$674K Sell
3,654
-105
-3% -$22.8K ﹤0.01% 1959
2026
Q2
$920K Buy
3,759
+37
+1% +$8.02K ﹤0.01% 1756
2026
Q1
$629K Sell
3,722
-3,731
-50% -$644K ﹤0.01% 1841
2025
Q4
$1.36M Buy
7,453
+1,716
+30% +$240K ﹤0.01% 1414
2025
Q3
$697K Buy
+5,737
New +$646K ﹤0.01% 1611
2023
Q1
– Sell
-350
Closed -$27K – 2127
2022
Q4
$27K Hold
350
– – ﹤0.01% 2675
2022
Q3
$15K Hold
350
– – ﹤0.01% 2890
2022
Q2
$13K Hold
350
– – ﹤0.01% 2973
2022
Q1
$14K Hold
350
– – ﹤0.01% 2876
2021
Q4
$13K Hold
350
– – ﹤0.01% 2831
2021
Q3
$11K Hold
350
– – ﹤0.01% 2833
2021
Q2
$23K Hold
350
– – ﹤0.01% 2418
2021
Q1
$19K Hold
350
– – ﹤0.01% 2295
2020
Q4
$28K Sell
350
-2,000
-85% -$150K ﹤0.01% 1872
2020
Q3
$167K Hold
2,350
– – ﹤0.01% 1101
2020
Q2
$193K Hold
2,350
– – ﹤0.01% 960
2020
Q1
$138K Buy
+2,350
New +$191K ﹤0.01% 917

Other funds holding AXSM

Rockefeller Capital Management's AXSM Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Axsome Therapeutics (AXSM) stake by 2.8% in Q3 2026, selling an estimated $22.8K and leaving 3,654 shares worth $674K. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Rockefeller Capital Management first reported a position in AXSM in Q1 2020 and has held it in 17 quarters since. The position peaked at $1.36M in Q4 2025. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Rockefeller Capital Management held 3,654 shares of Axsome Therapeutics worth $674K as of Q3 2026.
  • Rockefeller Capital Management sold 105 Axsome Therapeutics shares in Q3 2026, an estimated $22.8K.
  • Axsome Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #1959 holding.
  • Rockefeller Capital Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • Rockefeller Capital Management's Axsome Therapeutics position peaked at $1.36M in Q4 2025.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.